These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813 [TBL] [Abstract][Full Text] [Related]
5. Imatinib sensitizes CLL lymphocytes to chlorambucil. Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290 [TBL] [Abstract][Full Text] [Related]
6. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Panasci L; Paiement JP; Christodoulopoulos G; Belenkov A; Malapetsa A; Aloyz R Clin Cancer Res; 2001 Mar; 7(3):454-61. PubMed ID: 11297233 [TBL] [Abstract][Full Text] [Related]
7. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527 [TBL] [Abstract][Full Text] [Related]
8. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL). Pu Q; Bianchi P; Bezwoda WR Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327 [TBL] [Abstract][Full Text] [Related]
9. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459 [TBL] [Abstract][Full Text] [Related]
10. Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes. Bank BB; Kanganis D; Liebes LF; Silber R Cancer Res; 1989 Feb; 49(3):554-9. PubMed ID: 2910477 [TBL] [Abstract][Full Text] [Related]
11. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937 [TBL] [Abstract][Full Text] [Related]
12. Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Täger M; Kröning H; Thiel U; Ansorge S Exp Hematol; 1997 Jul; 25(7):601-7. PubMed ID: 9216735 [TBL] [Abstract][Full Text] [Related]
13. DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia. Müller MR; Buschfort C; Thomale J; Lensing C; Rajewsky MF; Seeber S Clin Cancer Res; 1997 Nov; 3(11):2055-61. PubMed ID: 9815597 [TBL] [Abstract][Full Text] [Related]
14. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line. Pu QQ; Bezwoda WR Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328 [TBL] [Abstract][Full Text] [Related]
15. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993 [TBL] [Abstract][Full Text] [Related]
16. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Begleiter A; Mowat M; Israels LG; Johnston JB Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099 [TBL] [Abstract][Full Text] [Related]
17. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052 [TBL] [Abstract][Full Text] [Related]
18. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. Secchiero P; di Iasio MG; Gonelli A; Barbarotto E; Melloni E; Tiribelli M; Chiaruttini C; Zauli G J Cell Physiol; 2007 Oct; 213(1):229-36. PubMed ID: 17476690 [TBL] [Abstract][Full Text] [Related]
19. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742 [TBL] [Abstract][Full Text] [Related]
20. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]